Advancing role of radiolabeled antibodies in the therapy of cancer

Cancer Immunology, Immunotherapy

Volumn 52, Issue 5, 2003, Pages 281-296

  Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

Antibodies; Cancer; Radioimmunotherapy; Therapy

Indexed keywords

ANTIBODY; ANTIBODY CONJUGATE; CARCINOEMBRYONIC ANTIBODY; EPRATUZUMAB; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3; MONOCLONAL ANTIBODY CD20; MONOCLONAL ANTIBODY LYM 1; MONOCLONAL ANTIBODY NR LU 10; ONCOLYM; PENTACEA; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANTIBODY SPECIFICITY; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER STAGING; CARDIOPULMONARY INSUFFICIENCY; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DIARRHEA; HAIR LOSS; HISTOPATHOLOGY; HUMAN; HYPOTHYROIDISM; ISOTOPE LABELING; LIVER TOXICITY; METASTASIS; MUCOSA INFLAMMATION; MYELODYSPLASIA; NAUSEA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0037615120     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0348-5     Document Type: Conference Paper

References (139)

1. Akabani G, Cokgor I, Coleman RE, Gonzalez Trotter D, Wong TZ, Friedman HS, Friedman AH, Garcia-Turner A, Herndon JE, DeLong D, McLendon RE, Zhae XG, Pegram CN, Provenzale JM, Bigner DD, Zalutsky MR (2000) Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys 46:947-958
2. Amdur R, Bedfore J (1994) Dose-rate effects between 0.3 and 30 Gy/h in a normal and a malignant human cell line. Int J Radiat Oncol Biol Phys 30:83-90
3. 211 At-rituximab against non-Hodgkin lymphoma cells. Br J Cancer 83:1375-1379
4. Axworthy DB, Reno JM, Hylarides MD, Mallett RW, Theodore LJ, Gustavson LM, Su F, Hobson LJ, Beaumier PL, Fritzberg AR (2000) Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A 97:1802-1807
5. Barbet J, Kraeber-Bodere F, Vuillez JP, Gautherot E, Rouvier E, Chatal JF (1999) Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm 14:153-166
6. Bardies M, Bardet S, Faivre-Chauvet A, Peltier P, Douillard JY, Mahe M, Fiche M, Lisbona A, Giacalone F, Meyer P, Gautherot E, Rouvier E, Barber J, Chatal JF (1996) Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. J Nucl Med 37:1853-1859
7. Baum RP, Niesen A, Hertel A, Adams S, Kojouharoff G, Goldenberg DM, Hor G (1994) Initial clinical results with technetium-99m-labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas. Cancer 73:896-899
8. Behr TM, Blumenthal RD, Memtsoudis S, Sharkey RM, Gratz S, Becker W, Goldenberg DM (2000) Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments. Clin Cancer Res 6:4900-4907
9. Behr TM, Liersch T, Greiner-Bechert L, Griesinger F, Behe M, Markus PM, Gratz S, Angerstein C, Brittinger G, Becker H, Goldenberg DM, Becker W (2002) Radioimmunotherapy of small volume disease of metastatic colorectal cancer. Cancer 94 (Suppl):1373-1381
10. Behr TM, Memtsoudis S, Sharkey RM, Blumenthal RD, Dunn RM, Gratz S, Wieland E, Nebendahl K, Schmidberger H, Goldenberg DM, Becker W (1998) Experimental studies on the role of antibody fragments in cancer radioimmunotherapy: influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. Int J Cancer 77:787-795
11. Behr TM, Salib AL, Liersch T, Behe M, Angerstein C, Blumenthal RD, Fayyazi A, Sharkey RM, Ringe B, Becker H, Wormann B, Hiddemann W, Goldenberg DM, Becker W (1999) Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study. Clin Cancer Res 5:3232s-3242s
12. Behr TM, Sharkey RM, Juweid M, Dunn RM, Ying Z, Zhang CH, Siegel JA, Goldenberg DM (1997) Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin antibodies. J Nucl Med 38:409-418
13. Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Ying Z, Zhang CH, Swayne LC, Vardi Y, Siegel JA, Goldenberg DM (1997) Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med 38:858-870
14. Behr TM, Sharkey RM, Juweid MN, Dunn RM, Ying Z, Zhang CH, Siegel JA, Gold DV, Goldenberg DM (1996) Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors. Cancer Res 56:1805-1816
15. Behr TM, Wormann B, Gramatzki M, Riggert J, Gratz S, Behe M, Griesinger F, Sharkey RM, Kolb HJ, Hiddemann W, Goldenberg DM, Becker W (1999) Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. Clin Cancer Res 5:3304s-3314s
16. Blumenthal RD, Kashi R, Sharkey RM, Goldenberg DM (1995) Quantitative and qualitative effects of experimental radioimmunotherapy on tumor vascular permeability. Int J Cancer 61:557-566.
17. Blumenthal RD, Lew W, Juweid M, Alisauskas R, Ying Z, Goldenberg DM (2000) Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy. Cancer 88:333-343
18. Blumenthal RD, Sharkey RM, Haywood L, Natale AM, Wong GY, Siegel JA, Kennel SJ, Goldenberg DM (1992) Targeted therapy of athymic mice bearing GW-39 human-colonic-cancer micrometastases with I-131 labeled monoclonal antibodies. Cancer Res 52:6036-6044
19. 131I-labelled antibodies and their fragments in the GW-39 colonic cancer xenograft model. Int J Cancer 44:292-300
20. Blumenthal RD, Sharkey RM, Kashi R, Sides K, Stein R, Goldenberg DM (1997) Changes in tumor vascular permeability in response to experimental radioimmunotherapy: a comparative study of 11 xenografts. Tumour Biol 18:367-377.
21. Blumenthal RD, Taylor A, Osorio L, Ochakovskaya R, Raleigh JA, Papadoupoulou M, Bloomer WD, Goldenberg DM (2001) Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia. Int J Cancer 94:564-571
22. Boerman OC, Kranenborg MH, Oosterwijk E, Griffiths GL, McBride WJ, Oyen WJ, de Weijert M, Oosterwijk-Wakka J, Hansen HJ, Corstens FH (1999) Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate. Cancer Res 59:4400-4405
23. Brady LW, Markoe AM, Woo DV, Rackover MA, Koprowski H, Steplewski Z, Peyster RG (1990) Iodine 125-labeled anti-epidermal growth factor receptor 425 in the treatment of malignant astrocytomas: a pilot study. J Neurosurg Sci 34:243-249
24. 125I-labeled monoclonal antibody against epidermal growth factor receptor. Antib Immunoconjug Radiopharm 3:169-179
25. 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin. Cancer Biother Radiopharm 14:381-395
26. 90Y-DOTA- biotin. J Nucl Med 41:131-140
27. Buchegger F, Allal AS, Roth A, Papazyan JP, Dupertuis Y, Mirimanoff RO, Gillet M, Pelegrin A, Mach JP, Slosman DO (2000) Combined radioimmunotherapy and radiotherapy of liver metastases from colorectal cancer: a feasibility study. Anticancer Res 20:1889-1896
28. Buchegger F, Roth A, Allal A, Dupertuis YM, Slosman DO, Delaloye AB, Mach JP (2000) Radioimmunotherapy of colorectal cancer liver metastases: combination with radiotherapy. Ann N Y Acad Sci 910:263-269
29. Buchsbaum DJ (2000) Experimental radioimmunotherapy. Semin Radiat Oncol 10:156-167
30. Burke PA, DeNardo SJ, Miers LA, Kukis DL, DeNardo GL (2002) Combined modality radioimmunotherapy. Promise and peril. Cancer 94 (Suppl):1320-1331
31. Chang CH, Sharkey RM, Rossi EA, Karacay H, McBride W, Hansen HJ, Chatal JF, Barget J, Goldenberg DM (2002) Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol Cancer Ther 1:553-563
32. Cheson BD (2003) Radioimmunotherapy of non-Hodgkin lymphomas. Blood 101:391-398
33. Cheson BD, Homing SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244-1253
34. DeNardo GL, DeNardo SJ (1995) Overview of obstacles and opportunities for radioimmunotherapy of cancer. In: Goldenberg DM (ed) Cancer therapy with radiolabeled antibodies. CRC Press, Boca Raton, Fla.
35. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 16:3246-3256
36. 1311-Lym-1 antibody. Cancer Biother Radiopharm 13:239-254
37. DeNardo GL, Juweid ME, White CA, Wiseman GA, DeNardo SJ (2001) Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. Crit Rev Oncol Hematol 39:203-218
38. 131I-Lym-1. Int J Biol Markers 10:67-74
39. 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. Clin Cancer Res 5:533-541
40. DeNardo SJ, Kroger LA, Denardo GL (1999) A new era for radiolabeled antibodies in cancer? Curr Opin Immunol 11:563-569
41. DeNardo SJ, Kroger LA, MacKenzie MR, Mirick GR, Shen S, DeNardo GL (1998) Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody. Cancer Biother Radiopharm 13:1-12
42. DeNardo SJ, Kukis DL, Kroger LA, O'Donnell RT, Lamborn KR, Miers LA, DeNardo DG, Meares CF, DeNardo GL (1997) Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci U S A 94:4000-4004
43. Dillman RO (2002) Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 20:3545-35557
44. Eary JF, Press OW, Badger CC, Durack LD, Richter KY, Addison SJ, Krohn KA, Fisher DR, Porter BA, Williams DL (1990) Imaging and treatment of B-cell lymphoma. J Nucl Med 31:1257-1268
45. 131I-labeled bivalent hapten. J Nucl Med 41:480-487
46. Goldenberg DM (1993) Monoclonal antibodies in cancer detection and therapy. Am J Med 94:297-312
47. Goldenberg DM (ed) (1995) Cancer therapy with radiolabeled antibodies. CRC Press, Boca Raton, Fla.
48. Goldenberg DM (2001) The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol 39:195-201
49. Goldenberg DM (2001) Radioimmunotherapy. In: Freeman LM (ed) Nuclear medicine annual 2001. Lippincott, Williams & Wilkins, Philadelphia
50. Goldenberg DM (2002) Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 43:693-713
51. Goldenberg DM (2002) Studies of immunoscintigraphy and radioimmunotherapy in breast cancer. Semin Breast Dis 5:142-155
52. Goldenberg DM, Blumenthal RD, Sharkey RM (1990) Biological and clinical perspectives of cancer imaging and therapy with radiolabeled antibodies. Semin Cancer Biol 1:217-225
53. Goldenberg DM, DeLand F, Kim E, Bennett S, Primus FJ, van Nagell JR Jr, Estes N, DeSimone P, Rayburn P (1978) Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 298:1384-1388
54. Goldenberg DM, Gaffar SA, Bennett SJ, Beach JL (1981) Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res 41: 4354-4360
55. Goldenberg DM, Horowitz JA, Sharkey RM, Hall TC, Murthy S, Goldenberg H, Lee RE, Stein R, Siegel JA, Izon DO (1991) Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 9:548-564
56. Goldenberg DM, Kim EE, DeLand, FH, Bennett S, Primus FJ (1980) Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen. Cancer Res 40:2984-2992
57. Goodwin DA. Strategies for antibody targeting (1991) Antib Immunoconj Radiopharm 4:427-434
58. Goodwin DA, Meares CF, McCall MJ, McTigue M, Chaovapong W (1998) Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med 29:226-234
59. Gopal AK, Rajendran JG, Petersdorf SH, Maloney DG, Eary JF, Wood BL, Gooley TA, Bush SA, Durack LD, Martin PJ, Matthews DC, Appelbaum FR, Bernstein ID, Press OW (2002) High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99:3158-3162
60. Govindan SV, Goldenberg DM, Hansen HJ, Griffiths GL (2000) Advances in the use of monoclonal antibodies in cancer radiotherapy. Pharm Sci Techn Today 3:90-98
61. Griffith MH, Yorke ED, Wessels BW, DeNardo GL, Neacy WP (1992) Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy. J Nucl Med 33:2020-2023
62. 90Y-labeled epratuzumab (LymphoCide™; anti-CD22 monoclonal antibody) in relapsed refractory non-Hodgkin's lymphoma (NHL) (abstract). J Nucl Med 42 (Suppl):157P
63. Hansen HJ, Sullivan CL, Sharkey RM, Goldenberg DM (1993) HAMA interference with murine monoclonal antibody-based immunoassays. J Clin Immunoassay 16:294-299
64. Heath JK, White SJ, Johnstone CN, Catimel B, Simpson RJ, Moritz RL, Tu GF, Ji H, Whitehead RH, Groenen LC, Scott AM, Ritter G, Cohen L, Welt S, Old LJ, Nice EC, Burgess AW (1997) The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci U S A 94:469-474
65. Hnatowich DJ (1994) The in vivo uses of streptavidin and biotin: a short progress report. Nucl Med Commun 15:575-577
66. Illidge TM, Brock S (2000) Radioimmunotherapy of cancer: using monoclonal antibodies to target radiotherapy. Curr Pharm Des 6:1399-1418
67. Jurcic JG, Scheinberg DA (1995) Radioimmunotherapy of hematological cancer: problems and progress. Clin Cancer Res 1:1439-1446
68. 2. J Nucl Med 37:1504-1510
69. Juweid M, Sharkey RM, Markowitz A, Behr T, Swayne LC, Dunn R, Hansen HJ, Shevitz J, Leung SO, Rubin AD, Herskovic T, Hanley D, Goldenberg DM (1995) Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 55:5899s-5907s
70. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res 5:3292s-3303s
71. Kalofonos HP, Pawlikowska TR, Hemingway A, Courtenay-Luck N, Dhokia B, Snook D, Sivolapenko GB, Hooker GR, McKenzie CG, Lavender PJ (1989) Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med 30:1636-1645
72. Kaminski M, Zelenetz AD, Press O, Saleh M, Leonard J, Fehrenbacher L, Stagg R, Kroll S (1998) Multicenter, phase III study of iodine-131 tositumomab (anti-B1 antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma (abstract 1296). Blood 92:1296
73. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Cancer Res 96:1259-1266
74. Kemshead JT, Papanastassiou V, Coakham HB, Pizer BL (1992) Monoclonal antibodies in the treatment of central nervous system malignancies. Eur J Cancer 28:511-519
75. Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR, Colcher D, Horak ID, Weiner LM (2000) Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 6:406-414
76. Knox SJ, Goris ML, Wessels BW (1992) Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation. Radiother Oncol 23:111-117
77. Knox SJ, Meredith RF (2000) Clinical radioimmunotherapy. Semin Radiat Oncol 10:73-93
78. 131I-labeled bivalent DTPA hapten in patients with CEA-expressing tumor (abstract 459). J Nucl Med 42:123P
79. 131I-3F8. Med Pediatr Oncol 35:716-718
80. Larson SM, Pentlow KS, Volkow ND, Wolf AP, Finn RD, Lambrecht RM, Graham MC, Di Resta G, Bendriem B, Daghighian F (1992) PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med 33: 2020-2023
81. Leonard JP, Coleman M, Schuster MW, Feldman EJ, Chadburn A, Ely S, Sharkey RM, Hansen HJ, Wegener WA, Goldenberg DM (2000) Immunotherapy of NHL with Epratuzumab (anti-CD22 monoclonal antibody): excellent tolerability with objective responses (abstract 60). Proc Am Soc Clin Oncol 19:17a
82. Lewis JP, DeNardo GL, DeNardo SJ (1995) Radioimmunotherapy of lymphoma: a UC Davis experience. Hybridoma 14:115-120
83. Linden O, Tennvall J, Cavallin-Stahl E, Linder KJ, Darte L, Ohlsson T, Hindorf C, Wingardh K, Strand SE (2000) A phase I/II trial with Y-90 hLL2 in recurrent B-cell lymphomas, preliminary results (abstract 67). Cancer Biother Radiopharm 15:413
84. 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. Clin Cancer Res 5:3287s-3291s
85. Ling C, Spiro I, Stickler R (1984) Dose-rate effect between 1 and 10 Gy/min in a mammalian cell culture. Br J Radiol 57:723-728
86. Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, Matthews DC, Bush SA, Durack LD, Fisher DR, Gooley TA, Bernstein ID, Press OW (1998) Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 16:3270-3278
87. 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia 16:60-66.
88. McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, Wu K, Pellegrini V, Curcio MJ, Miederer M, Bander NH, Scheinberg DA (2000) Tumor therapy with targeted atomic nanogenerators. Science 294:1537-1540
89. Meredith RF, Buchsbaum DJ, Knox SJ (2000) Radionuclide dosimetry and radioimmunotherapy of cancer. In: Abrams AR, Fritzberg AR (eds) Radioimmunotherapy of cancer. Marcel Dekker, New York
90. 131Lyre-1 in patients with non-Hodgkin's lymphoma. Antib Immunoconj Radiopharm 6:1-11
91. Meredith RF, Khazaeli MB, Liu T, Plott G, Wheeler RH, Russell C, Colcher D, Schlom J, Shochat D, LoBuglio AF (1992) Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med 33:1648-1653
92. Meredith RF, LoBuglio AF, Spencer EB (1997) Recent progress in radioimmunotherapy for cancer. Oncology (Huntingt) 11:979-987
93. 125I-monoclonal antibody in the management of primary glioblastoma multiforme. Radiat Oncol Invest 3:126-132
94. 131I-CC49 in colorectal cancer. Cancer (Suppl) 73:1057-1066
95. Murray JL (1995) Radioimmunotherapy of colorectal cancer. In: Goldenberg DM (ed) Cancer therapy with radiolabeled antibodies. CRC, Boca Raton, Fla.
96. Murthy S, Sharkey RM, Goldenberg DM, Lee RE, Pinsky CM, Hansen HJ, Burger K, Swayne LC (1992) Lymphoma imaging with a new technetium-99m labeled antibody, LL2. Eur J Nucl Med 19:394-401
97. 67Copper-2- iminothiolane-6-[p-(bromocetamido)benzyl]-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma. Clin Cancer Res 5:3330s-3336s
98. Paganelli G, Grana C., Chinol M, Stabin MG, Grana C, Prisco G, Robertson C, Tosi G, Paganelli G (1999) Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 26:348-357
99. Paganelli G, Magnani P, Fazio F (1993) Pretargeting of carcinomas with the avidin-biotin system. Int J Biol Markers 8:155-159
100. Pawlak-Byczkowska EJ, Hansen HJ, Dion AS, Goldenberg DM (1989) Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma. Cancer Res 49:4568-4577
101. Pizer BL, Papanastassiou V, Moseley R (1991) Meningeal leukemia and medulloblastoma: preliminary experience with intrathecal radioimmunotherapy. Antib Immunoconj Radiopharm 4:753-761
102. 186Re-hLL2 (abstract 36). Cancer Biother Radiopharm 15:407
103. Postema EJ, Boerman OC, Oyen WJ, Raemaekers JM, Corstens FH (2001) Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Eur J Nucl Med 28:1725-1735
104. Press OW (1999) Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol 26:58-65
105. Press OW, Corcoran M, Subbiah K, Hamlin DK, Wilbur DS, Johnson T, Theodore L, Yau E, Mallett R, Meyer DL, Axworthy D (2001) A comparative evaluation of conventional and pretargeted radioimunotherapyof CD20-expressing lymphoma xenografts. Blood 98:2535-2543
106. Press OW, Eary JF, Appelbaum FR, Bernstein ID (1995) Treatment of relapsed B cell lymphomas with high-dose radioimmunotherapy and bone marrow transplantation. In: Goldenberg DM (ed) Cancer therapy with radiolabeled antibodies. CRC, Boca Raton, Fla.
107. Press OW, Eary JF, Applebaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B, Matthews DC, Fisher LD, Bernstein ID (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219-1224
108. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336-340
109. Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG, Maloney DG, Petersdorf S, Bush SA, Durack LD, Martin PJ, Fisher DR, Wood B, Borrow JW, Porter B, Smith JP, Matthews DC, Appelbaum FR, Bernstein ID (2000) A phase I/II trial of iodine-131-tositumomab (anti-CD-20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96:2934-2942
110. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH,Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD (2002) Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:1389-1397
111. Riva P, Francheschi G, Riva N, Casi M, Santimaria M, Adamo M (2000) Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur J Nucl Med 27:601-609
112. Riva P, Marangolo M, Tison V, Armaroli L, Moscatelli G, Franceschi G, Spinelli A, Vecchietti G, Morigi P, Tassini R (1991) Treatment of metastatic colorectal cancer by means of specific monoclonal antibodies conjugated with iodine 131: a phase II study. Nucl Med Biol 18:109-119
113. Rouvier E, Gautherot E, Meyer P, Barber J (1997) Targeting medullary thyroid carcinomas with bispecific antibodies and bivalent haptens. Results and clinical perspectives. Horm Res 47:163-167
114. Schlom J, Molinolo A, Simpson JF, Siler K, Roselli M, Hinkle G, Houchens DP, Colcher D (1990) Advantage of dose fractionation in monoclonal-antibody-targeted radioimmunotherapy. J Natl Cancer Inst 82:763-771
115. Sgouros G (1995) Radioimmunotherapy of micrometastases: sidestepping the solid tumor hurdle. J Nucl Med 36:1910-1912
116. Sharkey RM, Behr TM, Mattes MJ, Stein R, Griffiths GL, Shih LB, Hansen HJ, Blumenthal RD, Dunn RM, Juweid ME, Goldenberg DM (1997) Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother 44:179-188
117. Sharkey RM, Blumenthal RD, Behr TM, Wong GY, Haywood L, Forman D, Griffiths GL, Goldenberg DM (1997) Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma. Int J Cancer 72:477-485
118. Sharkey RM, Blumenthal RD, Hansen HJ, Goldenberg DM (1990) Biological considerations for radioimmunotherapy. Cancer Res 50:964s-969s
119. Sharkey RM, Karacay H, Griffiths GL, Behr TM, Blumenthal RD, Mattes MJ, Hansen HJ, Goldenberg DM (1997) Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model. Bioconjug Chem 8:595-604
120. Shih LB, Lu HH, Xuan H. Goldenberg DM (1994) Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int J Cancer 56:538-545
121. Siegel JA (1998) Revised Nuclear Regulatory Commission's regulations for release of patients administered radioactive materials: outpatient iodine 131 anti-B1 therapy. J Nucl Med [Supp] 39:28-33
122. Siegel JA, Goldenberg DM, Badger CC (1999) Radioimmunotherapy dose estimation in patients with B-cell lymphoma. Med Phys 20:579-582
123. Siegel JA, Yeldell D, Goldenberg DM, Stabin MG, Sparks RB, Sharkey RM, Brenner A, Blumenthal RD (2003) Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med 44:67-76
124. Tempero M, Leichner P, Dalrymple G, Harrison K, Augustine S, Schlam J, Anderson J, Wisecarver J, Colcher D (1997) High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. J Clin Oncol 15:1518-1528
125. 90yttrium-labeled monoclonal antibody CC49: a phase I trial. Clin Cancer Res 6:3095-3102
126. 131iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leuk Lymphoma 38:91-101
127. Vose JM (1999) Antibody-targeted therapy for low-grade lymphoma. Semin Hematol 36:15-20
128. Vuillez JP, Kraeber-Bodere F, Moro D, Bardies M, Douillard JY, Gautherot E, Rouvier E, Barber J, Garban F, Moreau P, Chatal JF (1999) Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 di-DTPA hapten: results of a phase I/II trial. Clin Cancer Res 5:3259s-3267s
129. Wahl RL (1994) Experimental radioimmunotherapy. A brief overview. Cancer (Supp) 73:989-992
130. 131 tositumomab radioimmunotherapy for previously untreated follicular lymphoma (FL) (abstract 309). J Nucl Med 41:78-79
131. Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S, Stone D, Axworthy D, Fisher D, Reno J (2000) Pretargeted radioimmunotherapy (PRIT™) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm 15:15-29
132. Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, Germain JS, Richards EC, Larson SM, Oettgen HF (1994) Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 12:1561-1571
133. Wilder RB, DeNardo GL, DeNardo SJ (1996) Radioimmunotherapy: recent results and future directions. J Clin Oncol 14:1383-1400
134. 90Y-Zevalin (yttrium-ibritumomab tiuxetan, IDIEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 27:766-777
135. 90yttrium radioimmunotherapy trial in non-Hodgkin's lymphoma (NHL) (abstract 260). J Nucl Med 40:64
136. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463
137. Witzig TE, Gordon LI, Wiseman GA, Spies S, Emmanouilides C, Czuczman MS, Flinn IW, Barlett NL, Murray JL, Alkuzweny B, Multani PS, Grillo-Lopez AJ, White CA (2000) Zevalin radioimmunotherapy is safe and well tolerated in patients with relapsed or refractory, B cell non-Hodgkin's lymphoma (NHL) (abstract 3160). Blood (Part 1):731a
138. Witzig TE, White CA, Flinn IW, Gordon L, Emmanouilides C, Cripe LD, Saleh M, Czuczman MS, Wiseman GA, Spies S, silverman DH, Burt RW, Olejnik T, Grillo-Lopez AJ (2000) Zevalin™ radioimmunotherapy of rituximab-refractory follicular non-Hodgkin's lymphoma (abstract 2183). Blood 96 (Part 1):507a
139. Zalutsky MR, Moseley RP, Benjamin JC, Colapinto EV, Fuller GN, Coakham HP, Bigner DD (1990) Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. Cancer Res 50:4105-4110